Back

Multimorbidity increases risk of cardiovascular outcomes in permanent atrial fibrillation: data from the RACE II study

30 March 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Poster session 3: clinical management of arrhythmias Epidemiology, Prognosis, Outcome EHRA Premium Access EHRA 2025 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Miss Colinda Van Deutekom

University Medical Centre Groningen, Groningen (Netherlands (The))

139 More presentations in this session

Presentation thumbnail
The relationship between left atrial electroanatomical voltage mapping and CMR-based fibrosis for enhanced preplanning in atrial fibrillation ablation
Doctor Z. Dadon (Jerusalem, IL)
Abstract Slides Video
Presentation thumbnail
Cardiac sympathetic denervation for different cardiovascular indications - the experience of two referral centers
Doctor A. Zienciuk-Krajka (Gdansk, PL)
Abstract
Presentation thumbnail
Practicing physicians perception of feasibility and usefulness of quality indicators of treatment for atrial fibrillation
Doctor J. Simic (Belgrade, RS)
Abstract Slides Video
Presentation thumbnail
Risk of left atrial thrombus in patients undergoing catheter ablation for atrial fibrillation and atrial flutter
Assistant Professor F. Guerra (Ancona, IT)
Abstract Slides Video
Presentation thumbnail
Clustering analysis of left atrial smax patterns: predicting atrial fibrillation termination and associations with key clinical factors
Mr J. Huh (Seoul, KR)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3: clinical management of arrhythmias

The Event

Event poster

EHRA 2025

30 March - 1 April 2025
You may be interested in
thumbnail
Congress Presentation
Multimorbidity increases risk of atrial fibrillation recurrence after cryoballoon ablation
thumbnail
Congress Presentation
Multimorbidity and risk of atrial fibrillation in the Lifelines Cohort
thumbnail
Congress Presentation
Prognostic implications of multimorbidity in patients with heart failure with mildly reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources